Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.16.3.1 (
ceruloplasmin
)
5,074
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
G9a
, a H3K9 methyltransferase, shows elevated expression in many types of human cancers, particularly breast cancer. However, the tumorigenic mechanism of
G9a
is still far from clear. Here we report that
G9a
exerts its oncogenic function in breast cancer by repressing hephaestin and destruction cellular iron homeostasis. In the case of pharmacological inhibition or short hairpin RNA interference-mediated suppression of
G9a
, the expression and activity of hephaestin increases, leading to the observed decrease of intracellular labile iron content and the disturbance of breast cancer cell growth in vitro and in vivo. We also provide evidence that
G9a
interacts with HDAC1 and YY1 to form a multi-molecular complex that contributes to hephaestin silencing. Furthermore, high
G9a
expression and low hephaestin expression correlate with poor survival of breast cancer are investigated. All these suggest a
G9a
-dependent epigenetic program in the control of iron homeostasis and tumor growth in breast cancer.
G9a
is a histone methyltransferase highly expressed in several cancers including breast cancer. Here the authors propose a mechanism through which
G9a
promotes breast cancer by regulating iron metabolism through the repression of
ferroxidase
hephaestin.
...
PMID:G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. 3270 95